EZH2 and medulloblastoma: Based on our studies using CRISPR-Cas 9 genome editing in mouse and human G3 MBs, a more thorough understanding of the consequences of tumor-specific epigenetic perturbation is warranted to avoid potentially detrimental therapeutic outcomes of EZH2 or EED inhibitory drugs in patients with medulloblastoma expressing high levels of EZH2.